Aytu BioPharma Is Maintained at Buy by Ascendiant Capital
Ratings actions from Benzinga: GMT) Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant CapitalRatings actions from Benzinga
Ratings actions from Benzinga: GMT) Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant CapitalRatings actions from Benzinga